Single User License
INR 168725
Site License
INR 337450
Corporate User License
INR 506175

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Pancreatic Cancer-Pipeline Review, H1 2015

Pancreatic Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Pancreatic Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Pancreatic Cancer-Pipeline Review, H1 2015', provides an overview of the Pancreatic Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Pancreatic Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 11

Pancreatic Cancer Overview 12

Therapeutics Development 13

Pancreatic Cancer-Therapeutics under Development by Companies 15

Pancreatic Cancer-Therapeutics under Investigation by Universities/Institutes 37

Pancreatic Cancer-Pipeline Products Glance 42

Pancreatic Cancer-Products under Development by Companies 46

Pancreatic Cancer-Products under Investigation by Universities/Institutes 75

Pancreatic Cancer-Companies Involved in Therapeutics Development 80

Pancreatic Cancer-Therapeutics Assessment 332

Drug Profiles 381

Pancreatic Cancer-Recent Pipeline Updates 1137

Pancreatic Cancer-Dormant Projects 1531

Pancreatic Cancer-Discontinued Products 1551

Pancreatic Cancer-Product Development Milestones 1556

Appendix 1565

List of Tables

Number of Products under Development for Pancreatic Cancer, H1 2015 64

Number of Products under Development for Pancreatic Cancer-Comparative Analysis, H1 2015 65

Number of Products under Development by Companies, H1 2015 67

Number of Products under Development by Companies, H1 2015 (Contd..1) 68

Number of Products under Development by Companies, H1 2015 (Contd..2) 69

Number of Products under Development by Companies, H1 2015 (Contd..3) 70

Number of Products under Development by Companies, H1 2015 (Contd..4) 71

Number of Products under Development by Companies, H1 2015 (Contd..5) 72

Number of Products under Development by Companies, H1 2015 (Contd..6) 73

Number of Products under Development by Companies, H1 2015 (Contd..7) 74

Number of Products under Development by Companies, H1 2015 (Contd..8) 75

Number of Products under Development by Companies, H1 2015 (Contd..9) 76

Number of Products under Development by Companies, H1 2015 (Contd..10) 77

Number of Products under Development by Companies, H1 2015 (Contd..11) 78

Number of Products under Development by Companies, H1 2015 (Contd..12) 79

Number of Products under Development by Companies, H1 2015 (Contd..13) 80

Number of Products under Development by Companies, H1 2015 (Contd..14) 81

Number of Products under Development by Companies, H1 2015 (Contd..15) 82

Number of Products under Development by Companies, H1 2015 (Contd..16) 83

Number of Products under Development by Companies, H1 2015 (Contd..17) 84

Number of Products under Development by Companies, H1 2015 (Contd..18) 85

Number of Products under Development by Companies, H1 2015 (Contd..19) 86

Number of Products under Development by Companies, H1 2015 (Contd..20) 87

Number of Products under Investigation by Universities/Institutes, H1 2015 89

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 90

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 91

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 92

Comparative Analysis by Late Stage Development, H1 2015 93

Comparative Analysis by Clinical Stage Development, H1 2015 94

Comparative Analysis by Early Stage Development, H1 2015 95

Comparative Analysis by Unknown Stage Development, H1 2015 96

Products under Development by Companies, H1 2015 97

Products under Development by Companies, H1 2015 (Contd..1) 98

Products under Development by Companies, H1 2015 (Contd..2) 99

Products under Development by Companies, H1 2015 (Contd..3) 100

Products under Development by Companies, H1 2015 (Contd..4) 101

Products under Development by Companies, H1 2015 (Contd..5) 102

Products under Development by Companies, H1 2015 (Contd..6) 103

Products under Development by Companies, H1 2015 (Contd..7) 104

Products under Development by Companies, H1 2015 (Contd..8) 105

Products under Development by Companies, H1 2015 (Contd..9) 106

Products under Development by Companies, H1 2015 (Contd..10) 107

Products under Development by Companies, H1 2015 (Contd..11) 108

Products under Development by Companies, H1 2015 (Contd..12) 109

Products under Development by Companies, H1 2015 (Contd..13) 110

Products under Development by Companies, H1 2015 (Contd..14) 111

Products under Development by Companies, H1 2015 (Contd..15) 112

Products under Development by Companies, H1 2015 (Contd..16) 113

Products under Development by Companies, H1 2015 (Contd..17) 114

Products under Development by Companies, H1 2015 (Contd..18) 115

Products under Development by Companies, H1 2015 (Contd..19) 116

Products under Development by Companies, H1 2015 (Contd..20) 117

Products under Development by Companies, H1 2015 (Contd..21) 118

Products under Development by Companies, H1 2015 (Contd..22) 119

Products under Development by Companies, H1 2015 (Contd..23) 120

Products under Development by Companies, H1 2015 (Contd..24) 121

Products under Development by Companies, H1 2015 (Contd..25) 122

Products under Development by Companies, H1 2015 (Contd..26) 123

Products under Development by Companies, H1 2015 (Contd..27) 124

Products under Development by Companies, H1 2015 (Contd..28) 125

Products under Investigation by Universities/Institutes, H1 2015 126

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 127

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 128

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 129

Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 130

Pancreatic Cancer-Pipeline by 3-V Biosciences, Inc., H1 2015 131

Pancreatic Cancer-Pipeline by 3B Pharmaceuticals GmbH, H1 2015 132

Pancreatic Cancer-Pipeline by 4SC AG, H1 2015 133

Pancreatic Cancer-Pipeline by AB Science, H1 2015 134

Pancreatic Cancer-Pipeline by AbbVie Inc., H1 2015 135

Pancreatic Cancer-Pipeline by AbGenomics International, Inc., H1 2015 136

Pancreatic Cancer-Pipeline by Ability Pharma, SL, H1 2015 137

Pancreatic Cancer-Pipeline by Adamed Sp. z o.o., H1 2015 138

Pancreatic Cancer-Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 139

Pancreatic Cancer-Pipeline by Aduro BioTech, Inc., H1 2015 140

Pancreatic Cancer-Pipeline by Advantagene, Inc., H1 2015 141

Pancreatic Cancer-Pipeline by Advaxis, Inc., H1 2015 142

Pancreatic Cancer-Pipeline by AGV Discovery, SAS, H1 2015 143

Pancreatic Cancer-Pipeline by AIMM Therapeutics B.V., H1 2015 144

Pancreatic Cancer-Pipeline by Alchemia Limited, H1 2015 145

Pancreatic Cancer-Pipeline by Alethia Biotherapeutics Inc., H1 2015 146

Pancreatic Cancer-Pipeline by Allinky Biopharma, H1 2015 147

Pancreatic Cancer-Pipeline by Almac Discovery Limited, H1 2015 148

Pancreatic Cancer-Pipeline by Altor BioScience Corporation, H1 2015 149

Pancreatic Cancer-Pipeline by Ambrx, Inc., H1 2015 150

Pancreatic Cancer-Pipeline by Ambryx Biotechnology, Inc., H1 2015 151

Pancreatic Cancer-Pipeline by Amgen Inc., H1 2015 152

Pancreatic Cancer-Pipeline by Anavex Life Sciences Corp., H1 2015 153

Pancreatic Cancer-Pipeline by ANP Technologies, Inc., H1 2015 154

Pancreatic Cancer-Pipeline by APEIRON Biologics AG, H1 2015 155

Pancreatic Cancer-Pipeline by Apexigen, Inc., H1 2015 156

Pancreatic Cancer-Pipeline by Aphios Corporation, H1 2015 157

Pancreatic Cancer-Pipeline by APIM Therapeutics AS, H1 2015 158

Pancreatic Cancer-Pipeline by Apogenix GmbH, H1 2015 159

Pancreatic Cancer-Pipeline by Aposense Ltd., H1 2015 160

Pancreatic Cancer-Pipeline by Aptose Biosciences Inc., H1 2015 161

Pancreatic Cancer-Pipeline by Arch Biopartners, Inc., H1 2015 162

Pancreatic Cancer-Pipeline by Argon Pharma S.L., H1 2015 163

Pancreatic Cancer-Pipeline by Array BioPharma Inc., H1 2015 164

Pancreatic Cancer-Pipeline by Ascenta Therapeutics, Inc., H1 2015 165

Pancreatic Cancer-Pipeline by Astellas Pharma Inc., H1 2015 166

Pancreatic Cancer-Pipeline by AstraZeneca Plc, H1 2015 167

Pancreatic Cancer-Pipeline by Aurigene Discovery Technologies Limited, H1 2015 168

Pancreatic Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 169

Pancreatic Cancer-Pipeline by Axcentua Pharmaceuticals AB, H1 2015 170

Pancreatic Cancer-Pipeline by Azaya Therapeutics Incorporated, H1 2015 171

Pancreatic Cancer-Pipeline by Basilea Pharmaceutica AG, H1 2015 172

Pancreatic Cancer-Pipeline by Bavarian Nordic A/S, H1 2015 173

Pancreatic Cancer-Pipeline by Bayer AG, H1 2015 174

Pancreatic Cancer-Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 175

Pancreatic Cancer-Pipeline by BerGenBio AS, H1 2015 176

Pancreatic Cancer-Pipeline by Beta Pharma, Inc., H1 2015 177

Pancreatic Cancer-Pipeline by Bexion Pharmaceuticals, LLC., H1 2015 178

Pancreatic Cancer-Pipeline by BioCancell Ltd, H1 2015 179

Pancreatic Cancer-Pipeline by Biogenomics Limited, H1 2015 180

Pancreatic Cancer-Pipeline by Biomar Microbial Technologies, H1 2015 181

Pancreatic Cancer-Pipeline by BioMarin Pharmaceutical Inc., H1 2015 182

Pancreatic Cancer-Pipeline by Biomunex Pharmaceuticals, H1 2015 183

Pancreatic Cancer-Pipeline by Bioncotech Therapeutics S.L., H1 2015 184

Pancreatic Cancer-Pipeline by Bionomics Limited, H1 2015 185

Pancreatic Cancer-Pipeline by BiOrion Technologies B.V., H1 2015 186

Pancreatic Cancer-Pipeline by Biotest AG, H1 2015 187

Pancreatic Cancer-Pipeline by Biothera, Inc., H1 2015 188

Pancreatic Cancer-Pipeline by Biouniversa s.r.l., H1 2015 189

Pancreatic Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 190

Pancreatic Cancer-Pipeline by Boston Biomedical, Inc., H1 2015 191

Pancreatic Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 192

Pancreatic Cancer-Pipeline by Calithera Biosciences, Inc., H1 2015 193

Pancreatic Cancer-Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 194

Pancreatic Cancer-Pipeline by Cavion LLC, H1 2015 195

Pancreatic Cancer-Pipeline by Celgene Corporation, H1 2015 196

Pancreatic Cancer-Pipeline by Cellectis S.A., H1 2015 197

Pancreatic Cancer-Pipeline by Celsion Corporation, H1 2015 198

Pancreatic Cancer-Pipeline by Centrose Llc, H1 2015 199

Pancreatic Cancer-Pipeline by Ceronco Biosciences, H1 2015 200

Pancreatic Cancer-Pipeline by ChemoCentryx, Inc., H1 2015 201

Pancreatic Cancer-Pipeline by Chiome Bioscience, Inc., H1 2015 202

Pancreatic Cancer-Pipeline by Clovis Oncology, Inc., H1 2015 203

Pancreatic Cancer-Pipeline by Confluence Life Sciences, Inc., H1 2015 204

Pancreatic Cancer-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 205

Pancreatic Cancer-Pipeline by Critical Outcome Technologies Inc., H1 2015 206

Pancreatic Cancer-Pipeline by CritiTech, Inc., H1 2015 207

Pancreatic Cancer-Pipeline by CrystalGenomics, Inc., H1 2015 208

Pancreatic Cancer-Pipeline by CTI BioPharma Corp., H1 2015 209

Pancreatic Cancer-Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015 210

Pancreatic Cancer-Pipeline by CureTech Ltd., H1 2015 211

Pancreatic Cancer-Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 212

Pancreatic Cancer-Pipeline by CytomX Therapeutics, Inc., H1 2015 213

Pancreatic Cancer-Pipeline by CytoVac A/S, H1 2015 214

Pancreatic Cancer-Pipeline by CytRx Corporation, H1 2015 215

Pancreatic Cancer-Pipeline by CZ BioMed Corp, H1 2015 216

Pancreatic Cancer-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 217

Pancreatic Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 218

Pancreatic Cancer-Pipeline by DEKK-TEC, Inc., H1 2015 219

Pancreatic Cancer-Pipeline by DiaMedica Inc., H1 2015 220

Pancreatic Cancer-Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015 221

Pancreatic Cancer-Pipeline by e-Therapeutics Plc, H1 2015 222

Pancreatic Cancer-Pipeline by Eisai Co., Ltd., H1 2015 223

Pancreatic Cancer-Pipeline by Eleison Pharmaceuticals, Inc., H1 2015 224

Pancreatic Cancer-Pipeline by Eli Lilly and Company, H1 2015 225

Pancreatic Cancer-Pipeline by Erytech Pharma SA, H1 2015 226

Pancreatic Cancer-Pipeline by Esperance Pharmaceuticals, Inc., H1 2015 227

Pancreatic Cancer-Pipeline by Etubics Corporation, H1 2015 228

Pancreatic Cancer-Pipeline by Exelixis, Inc., H1 2015 229

Pancreatic Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 230

Pancreatic Cancer-Pipeline by FibroGen, Inc., H1 2015 231

Pancreatic Cancer-Pipeline by Fujifilm Corporation, H1 2015 232

Pancreatic Cancer-Pipeline by Fusion Antibodies Limited, H1 2015 233

Pancreatic Cancer-Pipeline by Ganymed Pharmaceuticals AG, H1 2015 234

Pancreatic Cancer-Pipeline by Genelux Corporation, H1 2015 235

Pancreatic Cancer-Pipeline by Genentech, Inc., H1 2015 236

Pancreatic Cancer-Pipeline by Genmab A/S, H1 2015 237

Pancreatic Cancer-Pipeline by Gilead Sciences, Inc., H1 2015 238

Pancreatic Cancer-Pipeline by GlaxoSmithKline Plc, H1 2015 239

Pancreatic Cancer-Pipeline by Globeimmune, Inc., H1 2015 240

Pancreatic Cancer-Pipeline by GlycoMimetics, Inc., H1 2015 241

Pancreatic Cancer-Pipeline by Golden Biotechnology Corp., H1 2015 242

Pancreatic Cancer-Pipeline by Halozyme Therapeutics, Inc., H1 2015 243

Pancreatic Cancer-Pipeline by Heat Biologics, Inc., H1 2015 244

Pancreatic Cancer-Pipeline by Helix BioPharma Corp., H1 2015 245

Pancreatic Cancer-Pipeline by Huabo Biopharm Co., Ltd., H1 2015 246

Pancreatic Cancer-Pipeline by Hutchison MediPharma Limited, H1 2015 247

Pancreatic Cancer-Pipeline by Igenica Biotherapeutics, Inc., H1 2015 248

Pancreatic Cancer-Pipeline by Ignyta, Inc., H1 2015 249

Pancreatic Cancer-Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015 250

Pancreatic Cancer-Pipeline by Immodulon Therapeutics Ltd., H1 2015 251

Pancreatic Cancer-Pipeline by Immune Pharmaceuticals Inc., H1 2015 252

Pancreatic Cancer-Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2015 253

Pancreatic Cancer-Pipeline by Immunomedics, Inc., H1 2015 254

Pancreatic Cancer-Pipeline by Immunotope, Inc., H1 2015 255

Pancreatic Cancer-Pipeline by Immunovo BV, H1 2015 256

Pancreatic Cancer-Pipeline by Incuron, LLC, H1 2015 257

Pancreatic Cancer-Pipeline by Incyte Corporation, H1 2015 258

Pancreatic Cancer-Pipeline by Innopharmax Inc., H1 2015 259

Pancreatic Cancer-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 260

Pancreatic Cancer-Pipeline by Intezyne, Inc, H1 2015 261

Pancreatic Cancer-Pipeline by Intica Biomedical, Inc., H1 2015 262

Pancreatic Cancer-Pipeline by InvivoGen Therapeutics, H1 2015 263

Pancreatic Cancer-Pipeline by Io Therapeutics, Inc., H1 2015 264

List of Figures

Number of Products under Development for Pancreatic Cancer, H1 2015 64

Number of Products under Development for Pancreatic Cancer-Comparative Analysis, H1 2015 65

Number of Products under Development by Companies, H1 2015 66

Number of Products under Investigation by Universities/Institutes, H1 2015 88

Comparative Analysis by Late Stage Development, H1 2015 93

Comparative Analysis by Clinical Stage Development, H1 2015 94

Comparative Analysis by Early Stage Products, H1 2015 95

Assessment by Monotherapy Products, H1 2015 383

Assessment by Combination Products, H1 2015 384

Number of Products by Top 10 Targets, H1 2015 385

Number of Products by Stage and Top 10 Targets, H1 2015 385

Number of Products by Top 10 Mechanism of Actions, H1 2015 409

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 409

Number of Products by Top 10 Routes of Administration, H1 2015 428

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 428

Number of Products by Top 10 Molecule Types, H1 2015 430

Number of Products by Stage and Top 10 Molecule Types, H1 2015 430

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3-V Biosciences, Inc.

3B Pharmaceuticals GmbH

4SC AG

AB Science

AbbVie Inc.

AbGenomics International, Inc.

Ability Pharma, SL

Adamed Sp. z o.o.

Adamis Pharmaceuticals Corporation

Aduro BioTech, Inc.

Advantagene, Inc.

Advaxis, Inc.

AGV Discovery, SAS

AIMM Therapeutics B.V.

Alchemia Limited

Alethia Biotherapeutics Inc.

Allinky Biopharma

Almac Discovery Limited

Altor BioScience Corporation

Ambrx, Inc.

Ambryx Biotechnology, Inc.

Amgen Inc.

Anavex Life Sciences Corp.

ANP Technologies, Inc.

APEIRON Biologics AG

Apexigen, Inc.

Aphios Corporation

APIM Therapeutics AS

Apogenix GmbH

Aposense Ltd.

Aptose Biosciences Inc.

Arch Biopartners, Inc.

Argon Pharma S.L.

Array BioPharma Inc.

Ascenta Therapeutics, Inc.

Astellas Pharma Inc.

AstraZeneca Plc

Aurigene Discovery Technologies Limited

AVEO Pharmaceuticals, Inc.

Axcentua Pharmaceuticals AB

Azaya Therapeutics Incorporated

Basilea Pharmaceutica AG

Bavarian Nordic A/S

Bayer AG

Bellicum Pharmaceuticals, Inc.

BerGenBio AS

Beta Pharma, Inc.

Bexion Pharmaceuticals, LLC.

BioCancell Ltd

Biogenomics Limited

Biomar Microbial Technologies

BioMarin Pharmaceutical Inc.

Biomunex Pharmaceuticals

Bioncotech Therapeutics S.L.

Bionomics Limited

BiOrion Technologies B.V.

Biotest AG

Biothera, Inc.

Biouniversa s.r.l.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Cantex Pharmaceuticals, Inc.

Cavion LLC

Celgene Corporation

Cellectis S.A.

Celsion Corporation

Centrose Llc

Ceronco Biosciences

ChemoCentryx, Inc.

Chiome Bioscience, Inc.

Clovis Oncology, Inc.

Confluence Life Sciences, Inc.

Cornerstone Pharmaceuticals, Inc.

Critical Outcome Technologies Inc.

CritiTech, Inc.

CrystalGenomics, Inc.

CTI BioPharma Corp.

CureFAKtor Pharmaceuticals, LLC

CureTech Ltd.

Cyclacel Pharmaceuticals, Inc.

CytomX Therapeutics, Inc.

CytoVac A/S

CytRx Corporation

CZ BioMed Corp

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

DEKK-TEC, Inc.

DiaMedica Inc.

Dicerna Pharmaceuticals, Inc.

e-Therapeutics Plc

Eisai Co., Ltd.

Eleison Pharmaceuticals, Inc.

Eli Lilly and Company

Erytech Pharma SA

Esperance Pharmaceuticals, Inc.

Etubics Corporation

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

FibroGen, Inc.

Fujifilm Corporation

Fusion Antibodies Limited

Ganymed Pharmaceuticals AG

Genelux Corporation

Genentech, Inc.

Genmab A/S

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Globeimmune, Inc.

GlycoMimetics, Inc.

Golden Biotechnology Corp.

Halozyme Therapeutics, Inc.

Heat Biologics, Inc.

Helix BioPharma Corp.

Huabo Biopharm Co., Ltd.

Hutchison MediPharma Limited

Igenica Biotherapeutics, Inc.

Ignyta, Inc.

Ildong Pharmaceutical Co., Ltd.

Immodulon Therapeutics Ltd.

Immune Pharmaceuticals Inc.

ImmunoCellular Therapeutics, Ltd.

Immunomedics, Inc.

Immunotope, Inc.

Immunovo BV

Incuron, LLC

Incyte Corporation

Innopharmax Inc.

Inovio Pharmaceuticals, Inc.

Intezyne, Inc

Intica Biomedical, Inc.

InvivoGen Therapeutics

Io Therapeutics, Inc.

Ipsen S.A.

Isarna Therapeutics GmbH

Jasco Pharmaceuticals, LLC.

Jiangsu Hengrui Medicine Co., Ltd.

Kadmon Corporation, LLC

KAEL-GemVax Co., Ltd.

Kalos Therapeutics, Inc.

Kancera AB

Karyopharm Therapeutics, Inc.

Keystone Nano, Inc.

LivTech, Inc.

Lymphocyte Activation Technologies, S.A.

MabVax Therapeutics Holdings, Inc.

Meabco A/S

Mebiopharm Co., Ltd.

MediaPharma s.r.l.

Medicon Pharmaceuticals, Inc

MedImmune, LLC

Medivation, Inc.

Medivir AB

Merck & Co., Inc.

Merck KGaA

Merrimack Pharmaceuticals, Inc.

Millennium Pharmaceuticals, Inc.

Momenta Pharmaceuticals, Inc.

Morphotek, Inc.

MSM Protein Technologies, Inc.

Multimmune GmbH

Nanobiotix

NanoCarrier Co., Ltd.

Nanotherapeutics, Inc.

Natco Pharma Limited

NatureWise Biotech & Medicals Corporation

NeoPharm Co., Ltd.

Nerviano Medical Sciences S.r.l.

NewLink Genetics Corporation

Northwest Biotherapeutics, Inc.

Novartis AG

NuCana BioMed Limited

Omeros Corporation

Omnitura Therapeutics Inc.

Oncodesign SA

Oncogenex Pharmaceuticals, Inc.

Oncology Research International Limited

Oncolytics Biotech Inc.

Oncomatrix, S.L.

OncoMed Pharmaceuticals, Inc.

Oncothyreon Inc.

Oncovir, Inc.

Ono Pharmaceutical Co., Ltd.

Optimum Therapeutics, LLC

Oscotec Inc.

Otsuka Holdings Co., Ltd.

Peregrine Pharmaceuticals, Inc.

Pfizer Inc.

Pharma Mar, S.A.

Pharma Two B Ltd

PharmAbcine, Inc.

Pharmacyclics, Inc.

PharmaCyte Biotech, Inc.

Pharmedartis GmbH

Philogen S.p.A.

Phoenix Biotechnology, Inc.

Pique Therapeutics

Plexxikon Inc.

Polaris Pharmaceuticals, Inc.

Precision Biologics, Inc.

Prescient Therapeutics Ltd

Priaxon AG

Prima BioMed Ltd.

ProMetic Life Sciences Inc.

Qu Biologics Inc.

Quest PharmaTech Inc.

Quimatryx, S.L.

RedHill Biopharma Ltd.

Rexahn Pharmaceuticals, Inc.

Rigontec GmbH

Samyang Holdings Corporation

Sanofi

Sareum Holdings Plc

Sentinel Oncology Limited

SignPath Pharma Inc

Silence Therapeutics Plc

Solasia Pharma K.K.

Sunesis Pharmaceuticals, Inc.

Symphogen A/S

Synovo GmbH

Synta Pharmaceuticals Corp.

Tactic Pharma, LLC

Taiho Pharmaceutical Co., Ltd.

Taiwan Liposome Company, Ltd.

Takara Bio Inc.

Takeda Pharmaceutical Company Limited

Targovax AS

TetraLogic Pharmaceuticals

Teva Pharmaceutical Industries Limited

Threshold Pharmaceuticals, Inc.

Tokai Pharmaceuticals, Inc.

Tolero Pharmaceuticals, Inc.

Transgene SA

TVAX Biomedical, Inc.

Tyg Oncology Ltd.

ValiRx Plc

VasGene Therapeutics, Inc.

Vaxeal Holding SA

Vaximm AG

Vaxon Biotech

VCN Biosciences SL

Vertex Pharmaceuticals Incorporated

Virobay Inc.

vTv Therapeutics Inc.

Welichem Biotech Inc.

Wilex AG

XOMA Corporation

XTuit Pharmaceuticals, Inc.

Zeria Pharmaceutical Co Ltd

Zhejiang BetaPharma Co., Ltd.

Zymeworks Inc.

Pancreatic Cancer Therapeutic Products under Development, Key Players in Pancreatic Cancer Therapeutics, Pancreatic Cancer Pipeline Overview, Pancreatic Cancer Pipeline, Pancreatic Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com